Bank of America upgrades Bristol Myers to Buy, lifting its price target to $61 on pipeline catalysts, valuation support, and ...
If you are wondering whether Bristol-Myers Squibb is quietly becoming a value opportunity or just a classic value trap, you ...
24/7 Wall St. on MSN
Here Are Monday’s Top Wall Street Analyst Research Calls: Bristol-Myers Squibb, GE Vernova, KLA Corp., Klaviyo, Las Vegas Sands, ServiceNow, and More
Futures are trading higher on Monday as we head into the final trading weeks of 2025. All of the major indices were hit hard ...
StockStory.org on MSN
Why Bristol-Myers Squibb (BMY) stock is up today
What Happened? Shares of biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) jumped 2.6% in the afternoon session after ...
Detailed price information for Bristol-Myers Squibb Company (BMY-N) from The Globe and Mail including charting and trades.
Bristol Myers’ stock rallied Wednesday as investors maintained high hopes for Cobenfy as an Alzheimer’s treatment, even ...
Fintel on MSN
Morgan Stanley maintains Bristol-Myers Squibb Company - preferred security (BMYMP) underweight recommendation
Fintel reports that on December 12, 2025, Morgan Stanley maintained coverage of Bristol-Myers Squibb Company - Preferred Security (OTCPK:BMYMP) with a Underweight recommendation. Analyst Price ...
24/7 Wall St. on MSN
Here Are Friday’s Top Wall Street Analyst Research Calls: Bristol-Myers Squibb, Citigroup, Lululemon Athletica, PayPal, Roblox, Soundhound AI, and More
The futures are trading mixed as we get set to close out a wild and woolly week that saw a touch of just about everything.
Bristol Myers Squibb Bristol Myers Squibb (NYSE: BMY) recently reported its Q1 results, with revenues and earnings above the street estimates. The company reported revenue of $11.9 billion and an ...
A U.S. judge rejected Bristol Myers Squibb's bid to dismiss a lawsuit claiming it cheated shareholders of the former Celgene ...
Global interim Phase 2 data in locally advanced/metastatic triple-negative breast cancer (”TNBC”) show encouraging antitumor activity for ...
BioNTech and Bristol Myers Squibb share positive data from Phase 2 trial of pumitamig plus chemotherapy for triple-negative ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results